These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 19258738)
1. SERCA inhibition limits the functional effects of cyclic GMP in both control and hypertrophic cardiac myocytes. Zhang Q; Davidov T; Weiss HR; Scholz PM Pharmacology; 2009; 83(4):223-30. PubMed ID: 19258738 [TBL] [Abstract][Full Text] [Related]
2. Cyclic GMP-induced reduction in cardiac myocyte function is partially mediated by activation of the sarcoplasmic reticulum Ca(2+)-ATPase. Zhang Q; Yan L; Weiss HR; Scholz PM Pharmacology; 2002 Feb; 64(2):106-12. PubMed ID: 11803251 [TBL] [Abstract][Full Text] [Related]
3. Cyclic GMP signaling and regulation of SERCA activity during cardiac myocyte contraction. Zhang Q; Scholz PM; He Y; Tse J; Weiss HR Cell Calcium; 2005 Mar; 37(3):259-66. PubMed ID: 15670873 [TBL] [Abstract][Full Text] [Related]
4. Importance of ryanodine receptors in effects of cyclic GMP is reduced in thyroxine-induced cardiac hypertrophy. Zhang Q; Goel N; Rodriguez R; Scholz PM; Weiss HR Eur J Pharmacol; 2006 May; 537(1-3):45-51. PubMed ID: 16626695 [TBL] [Abstract][Full Text] [Related]
5. Negative functional effects of cGMP mediated by cGMP protein kinase are reduced in T4 cardiac myocytes. Engel S; Yan L; Weiss H; Scholz P Eur J Pharmacol; 2001 Jun; 421(1):23-30. PubMed ID: 11408045 [TBL] [Abstract][Full Text] [Related]
6. Interaction between the opposing functional effects of cyclic AMP and cyclic GMP in hypertrophic cardiac myocytes. Patel KN; Yan L; Gandhi A; Scholz PM; Weiss HR Basic Res Cardiol; 2001 Feb; 96(1):34-41. PubMed ID: 11215530 [TBL] [Abstract][Full Text] [Related]
7. Role of phospholamban in cyclic GMP mediated signaling in cardiac myocytes. Zhang Q; Scholz PM; Pilzak A; Su J; Weiss HR Cell Physiol Biochem; 2007; 20(1-4):157-66. PubMed ID: 17595525 [TBL] [Abstract][Full Text] [Related]
9. Effects of cyclic GMP and its protein kinase on the contraction of ventricular myocytes from hearts after cardiopulmonary arrest. Su J; Scholz PM; Tse J; Weiss HR Can J Physiol Pharmacol; 2004 Nov; 82(11):986-92. PubMed ID: 15644938 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of sarco(endo)plasmic reticulum Ca2+-ATPase differentially regulates contractile function in cardiac myocytes from normotensive and spontaneously hypertensive rats: role of Ca2+ regulatory proteins. Li SY; Golden KL; Jiang Y; Wang GJ; Privratsky JR; Zhang X; Eason AR; Culver B; Ren J Cell Biochem Biophys; 2005; 42(1):1-12. PubMed ID: 15673924 [TBL] [Abstract][Full Text] [Related]
11. Cyclic GMP protein kinase activity is reduced in thyroxine-induced hypertrophic cardiac myocytes. Yan L; Zhang Q; Scholz PM; Weiss HR Clin Exp Pharmacol Physiol; 2003 Dec; 30(12):943-50. PubMed ID: 14678234 [TBL] [Abstract][Full Text] [Related]
12. Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes. Weiss HR; Lazar MJ; Punjabi K; Tse J; Scholz PM Eur J Pharmacol; 2003 Nov; 481(1):25-31. PubMed ID: 14637171 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury. Abdallah Y; Gkatzoflia A; Pieper H; Zoga E; Walther S; Kasseckert S; Schäfer M; Schlüter KD; Piper HM; Schäfer C Cardiovasc Res; 2005 Apr; 66(1):123-31. PubMed ID: 15769455 [TBL] [Abstract][Full Text] [Related]
15. Reduction in interaction between cGMP and cAMP in dog ventricular myocytes with hypertrophic failure. Zhang Q; Lazar M; Molino B; Rodriguez R; Davidov T; Su J; Tse J; Weiss HR; Scholz PM Am J Physiol Heart Circ Physiol; 2005 Sep; 289(3):H1251-7. PubMed ID: 16100251 [TBL] [Abstract][Full Text] [Related]
16. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases. Weiss HR; Gong GX; Straznicka M; Yan L; Tse J; Scholz PM Can J Physiol Pharmacol; 1999 Jun; 77(6):422-31. PubMed ID: 10537228 [TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP reduces myocardial stunning through non-cyclic GMP protein kinase mechanisms. Zhang Q; Lazar M; Yan L; He Y; Tse J; Weiss HR; Scholz PM J Cardiovasc Pharmacol; 2004 Aug; 44(2):235-43. PubMed ID: 15243306 [TBL] [Abstract][Full Text] [Related]
18. Opposing functional effects of cyclic GMP and cyclic AMP may act through protein phosphorylation in rabbit cardiac myocytes. Yan L; Lee H; Huang MW; Scholz PM; Weiss HR J Auton Pharmacol; 2000 Apr; 20(2):111-21. PubMed ID: 11095549 [TBL] [Abstract][Full Text] [Related]
19. Functional interaction of a beta-adrenergic agonist and cyclic GMP phosphodiesterase inhibitor in control and hypertrophic cardiomyocytes. Zhang S; Rodriguez R; Scholz PM; Weiss HR Pharmacology; 2006; 76(2):53-60. PubMed ID: 16276122 [TBL] [Abstract][Full Text] [Related]
20. Interaction between cyclic GMP protein kinase and cyclic AMP may be diminished in stunned cardiac myocytes. Yan L; Patel KN; Zhang Q; Scholz PM; Weiss HR Eur J Pharmacol; 2001 Aug; 426(1-2):11-9. PubMed ID: 11525765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]